Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 4/2010

Open Access 01-04-2010 | Updates

Update in Women’s Health

Authors: Judith M. E. Walsh, MD, MPH, Mary S. Beattie, MD, MAS, Pamela Charney, MD

Published in: Journal of General Internal Medicine | Issue 4/2010

Login to get access

Excerpt

The aim of this clinical update is summarize articles and guidelines published in the last year that are scientifically rigorous and have the potential to impact women’s health clinical practice. …
Literature
1.
Spatz E, Canavan ME, Desai MM. From Here to JUPITERL: Identifying New Patients for Statin Thearpy Using Data From the 1999–2004 National Health and Nutrition Examination Survey. Vol. 2. Circulation: Cardiovascular Quality and Outcomes 2009; 41–8.
2.
Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med. 2008;168:713–20.CrossRefPubMed
3.
Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007;147:149–55.PubMed
4.
Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167:1145–51.CrossRefPubMed
5.
Cull CA, Neil HA, Holman RR. Changing aspirin use in patients with Type 2 diabetes in the UKPDS. Diabet Med. 2004;21:1368–71.CrossRefPubMed
6.
Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000–2001. J Intern Med. 2004;255:494–502.CrossRefPubMed
7.
Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study. Diabetes Care. 2008;31:1761–6.CrossRefPubMed
8.
Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, Fortmann SP, et al. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). Circulation. 2008;118:428–64.CrossRefPubMed
9.
Hollis JF, Gullion CM, Stevens VJ, Brantley PJ, Appel LJ, Ard JD, et al. Weight loss during the intensive intervention phase of the weight-loss maintenance trial. Am J Prev Med. 2008;35:118–26.CrossRefPubMed
10.
Jakicic JM, Marcus BH, Lang W, Janney C. Effect of exercise on 24-month weight loss maintenance in overweight women. Arch Intern Med. 2008;168:1550–9. Discussion 59–60.CrossRefPubMed
11.
Lobo RA. Treatment of the Postmenopausal Women-Basic and Clinical Aspects, 3rd Edition. Academic Press; 2007.
12.
Society NAM. Treatment of menopause-associated vasomotor symptoms: position statement of The Author is North American Menopause Society. Menopause. 2004;11:11–33.CrossRef
13.
Gynecologists ACoOa. Executive summary. Hormone therapy. Obstet Gynecol. 2004;104:1S.CrossRef
14.
Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499–503.CrossRefPubMed
15.
National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005; 142: 1003–13
16.
Woods NF, Smith-DiJulio K, Percival DB, Tao EY, Mariella A, Mitchell S. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Menopause. 2008;15:223–32.CrossRefPubMed
17.
NAM Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008;15:584–602.CrossRef
18.
Effectiveness and Safety of Vitamin D in Relation to Bone Health. Ottawa, Canada: University of Ottawa Evidence-based Practice Center; 2007.
19.
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–7.CrossRefPubMed
20.
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878–82.CrossRefPubMed
21.
Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:556–61.CrossRefPubMed
22.
23.
Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62(Suppl 3):10–21.PubMed
24.
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397–404.CrossRefPubMed
25.
Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L, et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry. 2006;163:79–87.CrossRefPubMed
26.
Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289:56–64.CrossRefPubMed
27.
Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Women’s Health Gend-Based Med. 2002;11:367–77.CrossRef
28.
Nurnberg HG, Hensley PL, Lauriello J, Parker LM, Keith SJ. Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatr Serv. 1999;50:1076–8.PubMed
29.
Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom. 1998;67:328–31.CrossRefPubMed
30.
Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG. 2003;110:1014–24.CrossRefPubMed
31.
Caruso S, Intelisano G, Farina M, Di Mari L, Agnello C. The function of sildenafil on female sexual pathways: a double-blind, cross-over, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2003;110:201–6.CrossRefPubMed
32.
Guy W. ECDEU Assessment manual for pharmacology. Washington: National Institute of Mental Health; 1976.
33.
Danforth KN, Townsend MK, Lifford K, Curhan GC, Resnick NM, Grodstein F. Risk factors for urinary incontinence among middle-aged women. Am J Obstet Gynecol. 2006;194:339–45.CrossRefPubMed
34.
Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG. 2003;110:247–54.CrossRefPubMed
35.
Melville JL, Katon W, Delaney K, Newton K. Urinary incontinence in US women: a population-based study. Arch Intern Med. 2005;165:537–42.CrossRefPubMed
36.
Waetjen LE, Liao S, Johnson WO, Sampselle CM, Sternfield B, Harlow SD, et al. Factors associated with prevalent and incident urinary incontinence in a cohort of midlife women: a longitudinal analysis of data: study of women's health across the nation. Am J Epidemiol. 2007;165:309–18.CrossRefPubMed
37.
Bump RC, Sugerman HJ, Fantl JA, McClish DK. Obesity and lower urinary tract function in women: effect of surgically induced weight loss. Am J Obstet Gynecol. 1992;167:392–7. discussion 97–9.PubMed
38.
Deitel M, Stone E, Kassam HA, Wilk EJ, Sutherland DJ. Gynecologic-obstetric changes after loss of massive excess weight following bariatric surgery. J Am Coll Nutr. 1988;7:147–53.PubMed
39.
Burgio KL, Richter HE, Clements RH, Redden DT, Goode PS. Changes in urinary and fecal incontinence symptoms with weight loss surgery in morbidly obese women. Obstet Gynecol. 2007;110:1034–40.PubMed
40.
Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS. Weight loss: a novel and effective treatment for urinary incontinence. J Urol. 2005;174:190–5.CrossRefPubMed
41.
Subak LL, Johnson C, Whitcomb E, Boban D, Saxton J, Brown JS. Does weight loss improve incontinence in moderately obese women? Int Urogynecol J Pelvic Floor Dysfunct. 2002;13:40–3.CrossRefPubMed
42.
43.
Borello-France D, Burgio KL. Nonsurgical treatment of urinary incontinence. Clin Obstet Gynecol. 2004;47:70–82.CrossRefPubMed
44.
Burgio KL. Behavioral treatment options for urinary incontinence. Gastroenterology. 2004;126:S82–9.CrossRefPubMed
45.
Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48:370–4.PubMed
46.
Mattiasson A, Blaakaer J, Hoye K, Wein AJ. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91:54–60.CrossRefPubMed
47.
Millard RJ. Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. Neurourol Urodyn. 2004;23:48–53.CrossRefPubMed
48.
Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst. 2004;96:1432–40.PubMedCrossRef
49.
Corsetti V, Ferrari A, Ghirardi M, Bergonzini R, Bellarosa S, Angelini O, et al. Role of ultrasonography in detecting mammographically occult breast carcinoma in women with dense breasts. Radiol Med. 2006;111:440–8.CrossRefPubMed
50.
Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR Am J Roentgenol. 2003;181:177–82.PubMed
51.
Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology. 2001;221:641–9.CrossRefPubMed
52.
Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243–53.CrossRefPubMed
53.
Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst. 1996;88:643–9.CrossRefPubMed
54.
Litherland JC, Stallard S, Hole D, Cordiner C. The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol. 1999;54:285–8.CrossRefPubMed
55.
Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen. 2001;8:29–34.CrossRefPubMed
56.
Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24:e49–50.CrossRefPubMed
57.
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.CrossRefPubMed
Metadata
Title
Update in Women’s Health
Authors
Judith M. E. Walsh, MD, MPH
Mary S. Beattie, MD, MAS
Pamela Charney, MD
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 4/2010
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-009-1199-y

Other articles of this Issue 4/2010

Journal of General Internal Medicine 4/2010 Go to the issue

Healing Arts

A Theory of Everything

Editorial

From the Editors’ Desk: Medicine as a Service Industry

Erratum

Erratum to: Primary Care Validation of a Single-Question Alcohol Screening Test

Original Article

Disparities in Service Quality Among Insured Adult Patients Seen in Physicians’ Offices

Original Article

Relationship of Opioid Use and Dosage Levels to Fractures in Older Chronic Pain Patients

Original Article

Rates and Predictors of Plans for Inferior Vena Cava Filter Retrieval in Hospitalized Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits